AKCA - アクセア・セラピュ―ティクス (Akcea Therapeutics Inc.) アクセア・セラピュ―ティクス

 AKCAのチャート


 AKCAの企業情報

symbol AKCA
会社名 Akcea Therapeutics Inc (アクセア・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 アクセル・セラピューティックス(Akcea Therapeutics Inc.)はバイオ医薬品会社である。同社は、脂質障害によって引き起こされる重篤な心筋代謝疾患を有する患者を治療するための薬物の開発・商業化に従事する。同社の医薬品バラネソーレン、AKCEA-APO(a)-LRx、AKCEA-ANGPTL3-LRx及びAKCEA-APOCIII-LRxはすべてIonis Pharmaceuticals Inc. (Ionis)によって開発されたアンチセンス技術に基く。同社のバラネッセルン薬は、家族性キロミクロン血症症候群(FCS)の治療用第III相臨床プログラムを完了し、家族性部分的脂肪異栄養症(FPL)治療の第III相臨床開発中にある。同社の臨床パイプラインには、上昇したトリグリセリド、酸化リン脂質および他のリポタンパク質(リポタンパク質またはLp(a))等の心筋代謝疾患の発生率の劇的な増加に寄与し、LDL-Cの上昇を超えて不十分に処理された脂質障害を治療する可能性のある薬物が含まれる。  アクセア・セラピュ―ティクスは米国のバイオ医薬品企業。後期の臨床段階で、主に脂質障害による心筋代謝疾患の治療薬の開発・商業化に従事する。遺伝性疾患などの病気を治療する可能性のある4種類の新薬パイプラインがある。アイオニス・ファ―マシュ―ティカルズの完全子会社で、ノバルティスと戦略的パ―トナ―シップを結ぶ。本社所在地はマサチュ―セッツ州ケンブリッジ。   Akcea Therapeutics, Inc. is a biopharmaceutical company. It engages in the development and marketing of drugs globally to treat patients with rare and serious diseases using antisense technology. Its primary focus is developing TEGSEDI, a therapy that treats the polyneuropathy caused by hereditary transthyretin-mediated amyloidosis in adults. It also offers a mature pipeline of novel drugs including AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx, and AKCEA-APOCIII-LRx. The company was founded in December 2014 and is headquartered in Cambridge, MA.
本社所在地 55 Cambridge Parkway Suite 100 Cambridge MA 02142 USA
代表者氏名 Christopher Gabrieli クリストファー・ガブリエル
代表者役職名 Chairman of the Board 取締役会会長
電話番号 +1 617-207-0202
設立年月日 41974
市場名 NASDAQ National Market System
ipoyear 2017年
従業員数 100人
url www.akceatx.com
nasdaq_url https://www.nasdaq.com/symbol/akca
adr_tso
EBITDA EBITDA(百万ドル) -131.02900
終値(lastsale) 28.495
時価総額(marketcap) 2442545010.14
時価総額 時価総額(百万ドル) 2563.836
売上高 売上高(百万ドル) 66.91400
企業価値(EV) 企業価値(EV)(百万ドル) 2181.985
当期純利益 当期純利益(百万ドル) -129.12800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Akcea Therapeutics Inc revenues increased from $11.8M to $35.4M. Net loss increased 9% to $91.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Pre-commercialization expenses increase from $4.1M to $33M (expense) Selling/General/Admin. E increase from $3.9M to $14.8M (expense).

 AKCAのテクニカル分析


 AKCAのニュース

   The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings  2020/08/02 15:08:50 Benzinga
Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts. COVID-19 news flow continued to pour in, with big pharma tie-ups flaunting positive tidings. In the biggest ever coronavirus funding deal, the Sanofi SA (NASDAQ: SNY ) GlaxoSmithKline plc (NYSE: GSK ) won a joint $2.1 billion U.S. federal funding award. Here're the key catalysts for the unfolding week: Conferences 72nd National Hemophilia Foundation's Annual Bleeding Disorders Meeting 2020 (virtual meeting): Aug. 1-8 PDUFA Dates FDA is scheduled to rule on DBV TECHNOLOGIE/S' ADR (NASDAQ: DBVT ) Viaskin peanut allergy patch Wednesday. However, cancellation of the Adcom meeting scheduled May 15 has poured cold water on the prospects of an approval coming through. Trevena Inc (NASDAQ: TRVN ) has a tryst with the FDA Friday, with respect to the NDA for its pain drug oleceridine, which was once rejected by the agency on the premise of inadequacy of clinical data.
   Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast  2020/07/21 11:00:00 PR Newswire
BOSTON, July 21, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., announced today that it will host a live webcast on Tuesday, August 4 at 4:30 p.m. Eastern Time to discuss its second quarter 2020 financial results and…
   Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference  2020/06/17 11:00:00 PR Newswire
BOSTON, June 17, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that Damien McDevitt, chief executive…
   Why Akcea (AKCA) Stock Might be a Great Pick  2020/05/11 12:32:00 Zacks Investment Research
Akcea (AKCA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace  2020/05/03 12:45:37 Benzinga
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual Conference): May 5–6 Maxim Group M-Vest Infectious Disease Virtual Conference: May 5 Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio Clinical Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is scheduled to present new data from the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet age-related macular degeneration.
   Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference  2020/06/17 11:00:00 PR Newswire
BOSTON, June 17, 2020 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious and rare diseases, today announced that Damien McDevitt, chief executive…
   Why Akcea (AKCA) Stock Might be a Great Pick  2020/05/11 12:32:00 Zacks Investment Research
Akcea (AKCA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace  2020/05/03 12:45:37 Benzinga
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual Conference): May 5–6 Maxim Group M-Vest Infectious Disease Virtual Conference: May 5 Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio Clinical Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is scheduled to present new data from the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet age-related macular degeneration.
   Earnings Preview: Akcea Therapeutics (AKCA) Q1 Earnings Expected to Decline  2020/04/28 16:34:01 Zacks Investment Research
Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Were Hedge Funds Right About Akcea Therapeutics, Inc. (AKCA)?  2020/04/18 13:55:28 Yahoo Finance
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
   Why Akcea (AKCA) Stock Might be a Great Pick  2020/05/11 12:32:00 Zacks Investment Research
Akcea (AKCA) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
   The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace  2020/05/03 12:45:37 Benzinga
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck & Co., Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ). Merck disappointed by lowering its outlook, although sell-side stayed positive on the prospects. Presentations at the American Association of Cancer Research Virtual Conference created some volatility. Verastem Inc (NASDAQ: VSTM ) became a casualty of "not-so-impressive" clinical data on its Phase 1 asset VS-6766 that targets KRAS mutant advanced solid tumors. The stock shed about 57% to a low of $1.77 before recovering some lost ground. Here are the key catalysts for the unfolding week. Conferences SunTrust Robinson Humphrey 6th Annual Life Sciences Summit (Virtual Conference): May 5–6 Maxim Group M-Vest Infectious Disease Virtual Conference: May 5 Related Link: A Deep Dive On Coronavirus Vaccine Plays Moderna, Inovio Clinical Readouts Adverum Biotechnologies Inc (NASDAQ: ADVM ) is scheduled to present new data from the OPTIC Phase1 clinical trial of ADVM-022 intravitreal gene therapy in wet age-related macular degeneration.
   Earnings Preview: Akcea Therapeutics (AKCA) Q1 Earnings Expected to Decline  2020/04/28 16:34:01 Zacks Investment Research
Akcea Therapeutics (AKCA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
   Were Hedge Funds Right About Akcea Therapeutics, Inc. (AKCA)?  2020/04/18 13:55:28 Yahoo Finance
Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]
   Nationally Ranked Shareholder Rights Firm Labaton Sucharow Announces Proprietary Investigation of Akcea Therapeutics, Inc. (AKCA)  2020/04/09 17:02:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Labaton Sucharow LLP, a leading and award winning investor rights law firm, announces it is investigating potential breach of fiduciary duty claims on behalf of shareholders of Akcea Therapeutics, Inc. (NASDAQ: AKCA). Akcea is a development and commercialization company focused on helping patients with serious diseases. Akcea purports to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercializ

 関連キーワード  (医薬品 米国株 アクセア・セラピュ―ティクス AKCA Akcea Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)